Switzerland-based CDMO, Lonza Group, has reportedly offered to acquire New Jersey-based Catalent, says Reuters sources.
Sources say the two companies have failed to agree on a price so far. Lonza is reportedly actively looking for acquisitions.
Lonza expanded its U.S. presence with several small biopharma purchases as well as purchasing Arch Chemicals in 2011.
According to Bloomberg, Catalent had $1.83 billion in sales last year, with almost two-thirds coming from its oral technologies unit.
Read the Reuters coverage